Sparingvision
Develops gene-agnostic gene therapies for patients with inherited retinal diseases and other blinding conditions
Highlights
- New on EvolcAdded 2026-10-30
About Sparingvision
SparingVision develops photoreceptor-targeted gene therapies intended to preserve or restore vision. Its investigational programs include SPVN06 for neuroprotection and SPVN20 for neuroenhancement.
The therapies target inherited retinal diseases, including retinitis pigmentosa, as well as dry age-related macular degeneration and geographic atrophy. SparingVision is a clinical-stage company based in Paris, France, founded in 2016.
Product: Investigational gene-agnostic gene therapies targeting photoreceptors to preserve or restore vision.
Jobs at Sparingvision
No open positions listed right now.
More biotech & pharma companies
Spartha Medical
Biopolymer coatings and testing services that help healthcare and cross-sector companies prevent microbial contaminationNew on EvolcSpore.Bio
AI-based, culture-free microbial detection device and consumables for quality control in factories, from pharma and beveragesYoung companyRemote-friendlySqy Therapeutics
Develops antisense oligonucleotide drug candidates for people with genetic diseases, particularly Duchenne muscular dystrophyNew on EvolcStem Genomics
Genomic stability and cell identity testing for research and biotech labs working on human stem cellsNew on EvolcStemcell Technologies
Cell culture products, instruments and research services for life science researchers worldwideNew on EvolcSubstipharm
Develops and supplies medicines and vaccines for pharmaceutical partners and patients worldwideNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- WordPress
- jQuery
- nginx